<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663283</url>
  </required_header>
  <id_info>
    <org_study_id>18-005366</org_study_id>
    <nct_id>NCT03663283</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty</brief_title>
  <official_title>Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty: A Single Blinded Prospective Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if peripheral nerve block with liposomal&#xD;
      bupivacaine in combination with standard bupivacaine will prolong the duration of block,&#xD;
      improve pain scores, and decrease opioid utilization in the post-operative period when&#xD;
      compared to peripheral nerve block with standard bupivacaine alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-blinded randomized clinical trial comparing outcomes in&#xD;
      patients undergoing total shoulder arthroplasty (anatomic and reverse) who receive a&#xD;
      peripheral nerve block with liposomal bupivacaine in combination with standard bupivacaine&#xD;
      versus standard bupivacaine alone. Once consent is obtained, baseline characteristics will be&#xD;
      recorded and patients will be randomized to intervention or control. Following surgery,&#xD;
      patients will be followed until their 3-week post-operative visit. The primary outcome&#xD;
      measure will be the mean difference in patient pain scores over the first 72 hours&#xD;
      post-operatively between two groups. Secondary outcomes will include: (1) Total opioid&#xD;
      consumption (as measured utilizing morphine intravenous equivalents) in first 72 hours and at&#xD;
      3 weeks (2) Patient perceived duration of block determined as the time patient perceives&#xD;
      complete resolution of block (3) Patient satisfaction with pain control at 72 hours, 3 weeks&#xD;
      post-operatively and patient reported outcome measures (SANE, SST, ASES, VR-12) at 3 weeks&#xD;
      post-operatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">February 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The pharmacist will prepare, and dispense the medication sequentially. Medication syringes will be blinded utilizing black tape. Patients, care team in recovery, study team members collecting and recording data, and statisticians will be blinded to randomization assignment. All patients will be documented in EMR as receiving liposomal bupivacaine to ensure the blind is maintained and to ensure that safety features in the EMR for all patients receiving liposomal bupivacaine are activated. Further, all additional standard precautionary measures (e.g. wrist band) will be similarly implemented for both patient groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Pain Scores</measure>
    <time_frame>72 hours post-operatively</time_frame>
    <description>Patient pain scores over the first 72 hours post-operatively as measured by the Visual Analogue Scale where Zero represents no pain and ten represents severe pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>Measured at 72 hours and at 3 weeks post-operatively</time_frame>
    <description>Total opioid consumption as measured by morphine milligram equivalent (MME) in first 72 hours and at 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Nerve Blockade</measure>
    <time_frame>4, 8, 12, 16, 20, 24, and 28 hours post-operatively</time_frame>
    <description>Measured by the number of subjects who reported cessation of nerve blockade as the first reported postoperative pain score of 3 or greater at the surgical site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Pain Control Using Satisfaction Scale</measure>
    <time_frame>Measured at 72 hours and at three weeks post-operatively</time_frame>
    <description>Patient satisfaction with pain control at 72 hours post-operatively and three weeks post operatively using Patient Satisfaction with Pain Management Pain Scale where Zero represents unsatisfactory pain management and ten represents perfect pain management.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Arthropathy Shoulder</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Interscalene Nerve Blocks</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>Interscalene Nerve Blocks</description>
    <arm_group_label>Plain Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  All adult patients (&gt;18 years of age)&#xD;
&#xD;
          -  Patients undergoing standard or reverse total shoulder arthroplasty for the primary&#xD;
             diagnoses of glenohumeral arthritis or cuff tear arthropathy&#xD;
&#xD;
          -  Cognitively intact with the ability to give informed consent as outlined by our&#xD;
             institutional review board.&#xD;
&#xD;
          -  Patients must be capable of participating in the post-operative electronic survey and&#xD;
             / or able to maintain a written diary of events&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Non-elective cases&#xD;
&#xD;
          -  Infection, tumor, trauma&#xD;
&#xD;
          -  Weight &lt; 50 kg&#xD;
&#xD;
          -  Patients with any contraindications to regional anesthesia including allergy or&#xD;
             hypersensitivity to amide-type local anesthetics&#xD;
&#xD;
          -  Patients with allergy to any component of medication regimen e.g. amide- type local&#xD;
             anesthetics, oxycodone, hydromorphone, fentanyl&#xD;
&#xD;
          -  Chronic pain patients with history of chronic opioid use (defined as 20 mg morphine&#xD;
             equivalent / day for greater than 30 days pre-operatively&#xD;
&#xD;
          -  Concurrent painful physical condition that may require analgesic treatment that is not&#xD;
             related to the shoulder surgery (chronic peripheral neuropathy, radiculopathy, or&#xD;
             other neurologic disorder)&#xD;
&#xD;
          -  Severe hepatic disease defined by clinical evidence of liver disease with abnormal&#xD;
             liver function tests.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Respiratory disease that contraindicates interscalene nerve block (elevated&#xD;
             contralateral hemidiaphragm, contralateral pneumonectomy, or severe COPD with FEV1 &lt;&#xD;
             50% predicted, and 02 dependence)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Hattrup</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/33045330/</url>
    <description>PubMed</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <results_first_submitted>January 21, 2021</results_first_submitted>
  <results_first_submitted_qc>February 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Steven J. Hattrup, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03663283/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine</title>
          <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
        </group>
        <group group_id="P2">
          <title>Plain Bupivacaine</title>
          <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine</title>
          <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
        </group>
        <group group_id="B2">
          <title>Plain Bupivacaine</title>
          <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="6.84"/>
                    <measurement group_id="B2" value="69.2" spread="10.15"/>
                    <measurement group_id="B3" value="69.6" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Pain Scores</title>
        <description>Patient pain scores over the first 72 hours post-operatively as measured by the Visual Analogue Scale where Zero represents no pain and ten represents severe pain.</description>
        <time_frame>72 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
          </group>
          <group group_id="O2">
            <title>Plain Bupivacaine</title>
            <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Pain Scores</title>
          <description>Patient pain scores over the first 72 hours post-operatively as measured by the Visual Analogue Scale where Zero represents no pain and ten represents severe pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.57"/>
                    <measurement group_id="O2" value="2.8" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.0197</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption</title>
        <description>Total opioid consumption as measured by morphine milligram equivalent (MME) in first 72 hours and at 3 weeks</description>
        <time_frame>Measured at 72 hours and at 3 weeks post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
          </group>
          <group group_id="O2">
            <title>Plain Bupivacaine</title>
            <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Total opioid consumption as measured by morphine milligram equivalent (MME) in first 72 hours and at 3 weeks</description>
          <units>morphine milligram equivalent (MME)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="37.55"/>
                    <measurement group_id="O2" value="56.2" spread="35.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.9" spread="110.52"/>
                    <measurement group_id="O2" value="150.9" spread="138.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.584</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>3 weeks</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.5800</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Nerve Blockade</title>
        <description>Measured by the number of subjects who reported cessation of nerve blockade as the first reported postoperative pain score of 3 or greater at the surgical site.</description>
        <time_frame>4, 8, 12, 16, 20, 24, and 28 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
          </group>
          <group group_id="O2">
            <title>Plain Bupivacaine</title>
            <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Nerve Blockade</title>
          <description>Measured by the number of subjects who reported cessation of nerve blockade as the first reported postoperative pain score of 3 or greater at the surgical site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Pain Control Using Satisfaction Scale</title>
        <description>Patient satisfaction with pain control at 72 hours post-operatively and three weeks post operatively using Patient Satisfaction with Pain Management Pain Scale where Zero represents unsatisfactory pain management and ten represents perfect pain management.</description>
        <time_frame>Measured at 72 hours and at three weeks post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
          </group>
          <group group_id="O2">
            <title>Plain Bupivacaine</title>
            <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Pain Control Using Satisfaction Scale</title>
          <description>Patient satisfaction with pain control at 72 hours post-operatively and three weeks post operatively using Patient Satisfaction with Pain Management Pain Scale where Zero represents unsatisfactory pain management and ten represents perfect pain management.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.74"/>
                    <measurement group_id="O2" value="6.9" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.52"/>
                    <measurement group_id="O2" value="7.8" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.7018</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.5327</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline to treatment follow up visit, approximately 10 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine</title>
          <description>Administered utilizing ultrasound guidance by an anesthesiologist. Study patients received 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Liposomal Bupivacaine: Interscalene Nerve Blocks</description>
        </group>
        <group group_id="E2">
          <title>Plain Bupivacaine</title>
          <description>Peripheral nerve blocks were performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride was utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block was utilized. Further, 8 mg (2 ml) IV dexamethasone was administered concomitantly at the time of the block.&#xD;
Bupivacaine Hydrochloride: Interscalene Nerve Blocks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven J. Hattrup, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-301-8519</phone>
      <email>hattrup.steven@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

